

EA3163 Clinical Trial Results Summary

Testing the Addition of Chemotherapy to the Treatment of Cancer of the Sinonasal Area

What did this trial involve and who was it for?

A total of 29 patients participated in EA3163 out of a planned 82 patients. The study did not complete accrual due to the rarity of sinonasal cancer, but the results are striking. Participants enrolled in this study had nasal or paranasal sinus cancer that was planned to be treated with surgery followed by radiation—the usual treatment for these cancers. These surgeries usually involve the removal of some eye or bone structures in the base of skull. Some EA3163 participants were randomized to receive docetaxel and cisplatin (chemotherapy drugs) before the usual surgery, followed by radiation, while others received the usual treatment. The study hypothesized that treatment with these chemotherapy drugs prior to surgery, followed by radiation, would increase the likelihood that more bone could be preserved (would not need to be removed) during surgery.

What are the results?

Participants who received chemotherapy before surgery followed by radiation had a 50% chance of preserving eye or bone structures in the base of skull, while participants who received the usual care (surgery followed by radiation, without chemotherapy) had a 15% chance of preserving them.

What do the results mean for patients?

Although this trial was not powered to definitively answer the research question, the results provide evidence that treating patients with certain chemotherapy drugs before surgery, followed by radiation, for nasal or paranasal sinus cancers can increase the likelihood of preserving some eye or skull bone structures during surgery. Maintaining these structures can mean a better quality of life for patients after cancer treatment.

For more information, go to:

- United States National Institutes of Health (NIH) Library of Medicine: <https://clinicaltrials.gov/study/NCT03493425>
 - ECOG-ACRIN Press Release on EA3163's Results: <https://tinyurl.com/EA3163PressRelease>
 - *Annals of Oncology*: <https://doi.org/10.1016/j.annonc.2024.08.911>
 - Interview with Dr. Saba at ESMO 2024: <https://tinyurl.com/EA3163ESMOInterview>
-

About ECOG-ACRIN

This trial was led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). ECOG-ACRIN is a membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer. ECOG-ACRIN is a component of the National Cancer Institute's National Clinical Trials Network. Learn more at www.ecog-acrin.org.

To all the patients that participated in this trial, thank you. Without the involvement of patients like you, this research would not have been conducted.